All news

Moderna's 600% rally seen as unsustainable

Alpha Vantage · The Globe and Mail · · AI-summarised by FinFlash

Moderna shares have surged over 600% this year on positive trial results for its cancer vaccine intismeran combined with Merck's Keytruda, which showed strong effectiveness against melanoma. The article warns the valuation may be inflated, pricing in unconfirmed uses in other cancers while overlooking challenges in scaling personalized vaccine production and profit-sharing with Merck.

Read original source

MRNA company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.